Navigation Links
Caliper Life Sciences Added to Russell 3000(R) Index
Date:6/30/2008

HOPKINTON, Mass., June 30 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced that it has been added to the Russell 3000(R) Index.

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched last year.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4.4 trillion in assets currently are benchmarked to them. More information on the Russell 3000 and other Russell Indexes is available at http://www.russell.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper is a registered trademark of Caliper Life Sciences, Inc. Russell Investments is the owner of the trademarks, service marks and copyrights related to its indexes.

The statements in this press release include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors. Further information on risks faced by Caliper are detailed under the caption "Risks Related to Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2007. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
2. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
3. Caliper Life Sciences Reports West Coast Consolidation of Operations
4. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. Caliper Life Sciences Announces Date and Location of its 2008 Annual Meeting of Stockholders
7. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
8. Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference
9. Caliper Life Sciences to Present at Cowen and Company 28th Annual Health Care Conference
10. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
11. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for ... Breast Cancer Symposium. Using molecular test results from tumors with previously documented ...
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... YORK , Dec. 1, 2016   SurePure, ... photopurification, announced today that the Company has concluded an ... the right for a 90-day period to acquire units ... value of approximately USD 3.7 million.  ... agreement with Tamarack under which Tamarack will seek regulatory ...
(Date:11/30/2016)... 2016  GenomOncology today announced the appointment of Joshua ... Dr. Coleman will oversee clinical content development ... platform. The GenomOncology software suite empowers molecular pathologists with a ... clinical decision support, from quality control through reporting. ... , , ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):